INBRAIN’s graphene brain interface just cleared the boring test that matters first

INBRAIN Neuroelectronics has not proved that graphene can read minds. It has done something smaller and more useful: get a paper-thin brain sensor made from graphene, a form of carbon, through eight real tumor surgeries without reported device-related problems before patients left the hospital. For a field that usually sells the far future, that is the first practical test that matters.

The question is not whether Barcelona-based INBRAIN has built the cinematic version of a brain-computer interface. It is whether a softer sensor that sits on the brain's surface can help surgeons map speech and movement areas better than the metal electrodes they already use. If graphene wins there, the first real market for next-generation brain interfaces may look less like mind-reading demos and more like better tools in an operating room.

The timing needs a little deflation. The University of Manchester announced in September 2024 that INBRAIN's first human procedure had already taken place in a patient undergoing brain tumor resection, meaning surgical removal of a tumor. Manchester said the study would involve eight to 10 patients and was primarily meant to show that graphene could safely touch the human brain.

What is new now is enrollment completion and a fuller count of what happened. Medical Device Network reported that 10 patients were recruited, eight were surgically treated, and complete datasets were obtained from all eight treated patients. The same report said researchers saw no device-related adverse events through surgical discharge in those eight patients.

That is still a narrow safety claim, not a final verdict. The public evidence so far says the device did not obviously fail or cause device-related harm during the surgical window when doctors had to use it. It does not yet settle the longer follow-up questions that matter if this technology is going to graduate from an impressive operating-room demo to a dependable medical product.

The more ambitious claim is about signal quality. In some awake surgeries, patients performed tasks such as naming objects so the team could test whether the device could pick up speech-related brain activity with high precision, according to Medical Device Network. That matters because surgeons already place electrodes on the brain to identify tissue they need to avoid while removing tumors. If graphene films conform more closely to the brain and capture finer signals, they could improve that mapping job before they ever become the stuff of science-fiction marketing.

Kostas Kostarelos, a nanomedicine professor at the University of Manchester, made the sales pitch directly in comments quoted by Interesting Engineering: the system can capture neural signals with a fidelity and resolution that metals can barely see. That is still a company-adjacent claim, and the fuller dataset is not public yet. But it gets at the real benchmark here. Graphene does not need to unlock telepathy to matter. It needs to beat the metal grids surgeons already trust.

INBRAIN says its platform can scale to as many as 1,024 contacts, according to the company website. More contacts do not automatically mean better medicine. They do help explain why graphene keeps attracting attention. A flexible interface with denser sensing points could, in theory, collect a richer map from the brain's surface without forcing surgeons to work with a stiffer grid that sees less.

There is plenty of reason to stay skeptical. Much of the public record still runs through company-linked announcements and trade coverage rather than a peer-reviewed clinical paper. The treated cohort is eight patients. Barcelona Science Park reported in September 2025 that INBRAIN had raised $124 million, opened a U.S. office, and announced a Mayo Clinic collaboration, while the University of Manchester said in 2024 that the platform had received FDA Breakthrough Device Designation for Parkinson's disease. Those are real signals of ambition. They are not proof that the harder product claim already works.

That harder claim is the one worth watching. If fuller data show that graphene gives surgeons a cleaner, safer mapping layer than metal electrodes, then the first durable business for advanced brain interfaces may come from surgical mapping and monitoring, not the grander chronic-implant visions neurotech startups usually lead with. For once, the boring version of the story is the one with the best chance of becoming true.